Genomic Medicine Sweden was founded in 2018 with the aim of translating genomic innovation into clinical utility and implementing a sustainable precision medicine infrastructure in Sweden. Genomic Medicine Sweden is nationally funded through the Swedish Innovation Agency Vinnova and also through the seven regions with university hospitals and through the universities with a medical faculty. We bring together clinicians, researchers, private industry and patient organizations within a single organization with the goal of promoting and implementing precision medicine in healthcare and in conducting cutting-edge research and development.
The Genomic Medicine Sweden (GMS) initiative aims to pave the way to precision medicine and ultimately improve healthcare across Sweden. This is high on the agenda for the Governmental Life Science Office of Sweden and one of three prioritized areas for Sweden as a life science nation. Improved diagnostics and individualized treatment will be accomplished through the implementation of large-scale sequencing techniques within healthcare. As new technologies mature, the aim is also to include other “omics” technologies to provide next-generation diagnostics in healthcare.
Focus on three disease areas
The introduction of genomics into a health system is complex and as such GMS will undertake a phased approach. In the initial phase, GMS will focus on patients with rare inherited diseases, cancer (hematological malignancies, solid tumors and pediatric cancer) and infectious diseases. Pharmacogenomics, whereby specific genomic alterations may provide insights into drug sensitivity and/or resistance and thus help in avoiding adverse events and optimizing drug dosages, also forms part of the initial phase. The next phase encompasses complex diseases including, for example, cardiovascular and autoimmune diseases as well as psychiatric illnesses.
A national infrastructure comprising seven regional centers
Seven regional Genomic Medicine Centers (GMC) are being established across Sweden in Gothenburg, Linköping, Lund, Stockholm, Uppsala, Umeå and Örebro, thereby covering all healthcare regions throughout the country. Each GMC is a collaboration between the region with university hospital care, the university with a medical faculty and Science for Life Laboratory (SciLifeLab). These joint centers act as the primary point of contact for sequencing patient samples within healthcare, thereby creating an integrated platform for both healthcare delivery and advanced medical research. Over the coming years GMS will develop methods that enable a standardized introduction of genomic medicine in Swedish healthcare. At the same time, we are establishing a joint national infrastructure that will enable and facilitate the analysis, interpretation and storage of genetic data.
Research for the future
GMS also acts as a unique research resource and translational research hub for identifying disease-causing events that could pave the way for the development of new drugs, innovative healthcare solutions, and enhanced collaboration within the life science sector.
GMS: Facts and figures
- 2018 founded as a national initiative
- 14 partnering regions with university hospital care and universities with medical faculty
- 7 Genomic Medicine Centers
- 50,000 samples sequenced/year by 2023, covering the majority of Swedish patients with rare diseases and cancer
The GMS initiative is funded by the Swedish government, through the Swedish Innovation Agency Vinnova, and by the seven partnering regions and universities.
If you would like to find out more about GMS, how we work, and what we can offer then visit our full website (in Swedish) or get in touch with us:
E-mail us: email@example.com